Kopran Limited has achieved significant regulatory milestones in its proposed merger process, receiving observation letters with no adverse observations from both BSE Limited and NSE Limited for its scheme of amalgamation with Kopran Laboratories Limited.

Dual Exchange Approval Timeline

The company received sequential approvals from both major stock exchanges within a day of each other. BSE Limited issued its observation letter on February 26, 2026, followed by NSE Limited providing its no objection letter on February 27, 2026.

NSE Observation Letter Requirements

NSE has outlined comprehensive compliance requirements based on SEBI's comments dated February 26, 2026. The exchange emphasized mandatory disclosure requirements including all ongoing adjudication and recovery proceedings, prosecution initiated, and enforcement actions against the company, its promoters, and directors before NCLT and shareholders.

Key NSE compliance requirements include:

• Complete disclosure of all pending legal actions and their potential impact
• Submission of audited financials for the last three years of all entities involved
• No Objection Certificates from lending banks and financial institutions
• Mandatory demat form for proposed equity shares under the scheme
• Compliance status report filing through NEAPS system

Shareholding Pattern Disclosure Mandates

Both exchanges have mandated specific disclosure requirements regarding shareholding patterns. The companies must prominently display pre-scheme and post-scheme shareholding percentages of promoter/promoter group and public shareholders on the first page of the notice convening the shareholders meeting.

Regulatory Framework and Next Steps

The observation letters are issued under Regulation 37 of SEBI LODR Regulations, 2015, with both carrying six-month validity periods. The scheme involves Kopran Laboratories Limited as the transferor company merging with Kopran Limited as the transferee company under Sections 230-232 of the Companies Act, 2013.

Both exchanges have reserved rights to withdraw their no adverse observation stance if any submitted information is found incomplete, incorrect, misleading, or false. The merger scheme remains subject to applicable regulatory and other statutory approvals, including NCLT approval.

Document Availability and Communication

Kopran Limited has made both observation letters available on its website at the dedicated amalgamation section. The company initially announced the Board of Directors' decision to approve the scheme on March 20, 2025, subject to receipt of applicable regulatory approvals. Company Secretary Sunil Sodhani confirmed the NSE approval through official communication on February 28, 2026.

Kopran Limited has reported its third quarter financial results, showing a decline in key profitability metrics compared to the corresponding period last year. The pharmaceutical company's operational performance reflected challenges in maintaining its previous year's profitability levels.

Financial Performance Overview

The company's financial metrics for the third quarter demonstrate a year-over-year decline in both absolute EBITDA and margin performance.

EBITDA Performance Analysis

Kopran's EBITDA for the third quarter reached ₹178.00 million, representing a decrease from the ₹198.00 million recorded in the same quarter of the previous year. This decline of ₹20.00 million indicates operational challenges faced by the company during the reporting period.

Margin Compression

The company experienced significant margin compression during the quarter, with EBITDA margin declining to 9.14% from 11.93% year-over-year. This 279 basis points reduction in margin suggests pressure on the company's operational efficiency and cost management during the third quarter.

The margin compression alongside the absolute EBITDA decline indicates that the company faced challenges in maintaining its profitability levels compared to the previous year's performance in the corresponding quarter.